← Leaderboards
Marc Kopel Hellerstein
University Of California San Francisco
$9,825,255
Attributed
$9,825,255
Total exposure
25
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $821.7K · FY2005–12$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$9,825,255 · 25
By mechanism
R01$4,664,393 · 4
R37$3,911,957 · 1
M01$837,057 · 19
P01$411,848 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Melvin B. Heyman$7,841,306
- Joel Palefsky$28,104,336
- Warner C Greene$31,742,202
- Daniel J Lerner$801,753
- Kathleen M Giacomini$35,943,104
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHiv InfectionsAidsAids TherapyNutrition Related TagLipid MetabolismT LymphocyteBody CompositionProtease InhibitorRadiotracerHuman Immunodeficiency Virus 1Cell ProliferationWeight LossBioenergeticsHuman Therapy EvaluationCell Population StudyCachexiaAntiaids AgentHelper T LymphocyteCytotoxic T LymphocytePatient Oriented ResearchHormone Regulation /Control MechanismLymphocyte Proliferation
Grant awards (87)
Testing in vivo of HIV-immunopathogenic hypotheses using new kinetic techniques$451,177
R37 · FY2012 · AI · contact PI
Testing in vivo of HIV-immunopathogenic hypotheses using new kinetic techniques$434,130
R37 · FY2011 · AI · contact PI
Testing in vivo of HIV-immunopathogenic hypotheses using new kinetic techniques$437,985
R37 · FY2010 · AI · contact PI
Response to and signals of caloric restriction and intermittent feeding regimens$383,750
R01 · FY2010 · AG · contact PI
Testing in vivo of HIV-immunopathogenic hypotheses using new kinetic techniques$429,517
R37 · FY2009 · AI · contact PI
Response to and signals of caloric restriction and intermittent feeding regimens$383,750
R01 · FY2009 · AG · contact PI
Testing in vivo of HIV-immunopathogenic hypotheses using new kinetic techniques$415,450
R37 · FY2008 · AI · contact PI
T-Cell Kinetics and Sources--Effects of HIV and Therapy$335,946
R37 · FY2007 · AI · contact PI
T-Cell Kinetics and Sources--Effects of HIV and Therapy$16,028
R37 · FY2007 · AI · contact PI
T-Cell Kinetics and Sources--Effects of HIV and Therapy$369,849
R37 · FY2006 · AI · contact PI
T-Cell Kinetics and Sources--Effects of HIV and Therapy$340,875
R37 · FY2005 · AI
THIAZOLIDINEDIONES ON ADIPOCYTE KINETICS$132,657
M01 · FY2005 · RR
GENDER AND SEX HORMONE EFFECTS ON T CELL KINETICS IN HIV DISEASE$122,046
M01 · FY2005 · RR
METABOLIC PATHWAYS IN HIV INFECTION$96,271
M01 · FY2005 · RR
CELL KINETICS AND SECRETED PROTEINS RECOVERED FROM BODILY FLUIDS AND EXCRETA$24,468
M01 · FY2005 · RR
DEVELOPMENT OF A NON-INVASIVE KINETIC BIOMARKER IN VIVO IN HUMANS$14,518
M01 · FY2005 · RR
THIAZOLIDINEDIONE, METFORMIN AND SULFONYLUREA THERAPY FOR TYPE 2 DIABETES$13,212
M01 · FY2005 · RR
AN ANALYSIS OF SPERMATOGENESIS KINETICS$9,298
M01 · FY2005 · RR
T-Cell Kinetics and Sources--Effects of HIV and Therapy$340,875
R37 · FY2004 · AI
Directly Measured T Cell Dynamics in HIV Pathogenesis$331,875
R01 · FY2004 · AI
Thiazolidinediones on adipocyte kinetics$213,570
M01 · FY2004 · RR
Gender and sex hormone effects on T cell kinetics in HIV disease$138,288
M01 · FY2004 · RR
Metabolic pathways in HIV infection$57,279
M01 · FY2004 · RR
An analysis of spermatogenesis kinetics$3,963
M01 · FY2004 · RR
Thiazoladenedione, metformin and sulfonylurea therapy for type 2 diabetes$3,646
M01 · FY2004 · RR
Cell kinetics and secreted proteins recovered from bodily fluids and excreta$3,329
M01 · FY2004 · RR
ADIPOCYTE TURNOVER AND METABOLISM IN HIV-1 LIPOATROPHY$376,000
R01 · FY2003 · HL
T-Cell Kinetics and Sources--Effects of HIV and Therapy$340,125
R37 · FY2003 · AI
Directly Measured T Cell Dynamics in HIV Pathogenesis$331,875
R01 · FY2003 · AI
ADIPOCYTE TURNOVER AND METABOLISM IN HIV-1 LIPOATROPHY$376,000
R01 · FY2002 · HL
Directly Measured T Cell Dynamics in HIV Pathogenesis$315,281
R01 · FY2002 · AI
T CELL KINETICS AND SOURCES--EFFECTS OF HIV AND THERAPY$291,379
R01 · FY2002 · AI
HIV: GENDER AND SEX HORMONE EFFECTS ON T CELL KINETICS$205,924
P01 · FY2002 · HD
HIV: GENDER AND SEX HORMONE EFFECTS ON T CELL KINETICS$205,924
P01 · FY2002 · HD
HEPATIC LIPOGENESIS DURING FRUCTOSE INFUSION$0
M01 · FY2002 · RR
METABOLIC PATHWAYS, MONOKINES, AND WASTING IN HIV INFECTION$0
M01 · FY2002 · RR
METABOLIC PATHWAYS, MONOKINES, AND WASTING IN HIV INFECTION$0
M01 · FY2002 · RR
EFFICACY OF ORAL SUPPLEMENTS IN DIARRHEA AND WEIGHT LOSS$0
M01 · FY2002 · RR
EFFICACY OF ORAL SUPPLEMENTS IN DIARRHEA AND WEIGHT LOSS$0
M01 · FY2002 · RR
HEPATIC LIPOGENESIS DURING FRUCTOSE INFUSION$0
M01 · FY2002 · RR
DIRECTLY MEASURED T CELL DYNAMICS IN HIV PATHOGENESIS$0
M01 · FY2002 · RR
DIRECTLY MEASURED T CELL DYNAMICS IN HIV PATHOGENESIS$0
M01 · FY2002 · RR
SOURCES OF VLDL-TRIGLYCERIDE IN NIDDM$0
M01 · FY2002 · RR
SOURCES OF VLDL-TRIGLYCERIDE IN NIDDM$0
M01 · FY2002 · RR
METFORMIN AND METABOLISM/BODY COMPOSITION IN HIV/AIDS$0
M01 · FY2002 · RR
METFORMIN AND METABOLISM/BODY COMPOSITION IN HIV/AIDS$0
M01 · FY2002 · RR
PI AND METABOLISM/BODY COMPOSITION IN HIV - CONTROLS$0
M01 · FY2002 · RR
PI AND METABOLISM/BODY COMPOSITION IN HIV - CONTROLS$0
M01 · FY2002 · RR
ADIPOCYTE TURNOVER AND METABOLISM IN HIV-1 LIPOATROPHY$376,000
R01 · FY2001 · HL
Directly Measured T Cell Dynamics in HIV Pathogenesis$298,688
R01 · FY2001 · AI
T CELL KINETICS AND SOURCES--EFFECTS OF HIV AND THERAPY$283,023
R01 · FY2001 · AI
EFFICACY OF ORAL SUPPLEMENTS IN DIARRHEA AND WEIGHT LOSS$0
M01 · FY2001 · RR
METABOLIC PATHWAYS, MONOKINES, AND WASTING IN HIV INFECTION$0
M01 · FY2001 · RR
HIV: GENDER AND SEX HORMONE EFFECTS ON T CELL KINETICS$0
P01 · FY2001 · HD
PI AND METABOLISM/BODY COMPOSITION IN HIV - CONTROLS$0
M01 · FY2001 · RR
METFORMIN AND METABOLISM/BODY COMPOSITION IN HIV/AIDS$0
M01 · FY2001 · RR
SOURCES OF VLDL-TRIGLYCERIDE IN NIDDM$0
M01 · FY2001 · RR
DIRECTLY MEASURED T CELL DYNAMICS IN HIV PATHOGENESIS$0
M01 · FY2001 · RR
HEPATIC LIPOGENESIS DURING FRUCTOSE INFUSION$0
M01 · FY2001 · RR
ADIPOCYTE TURNOVER AND METABOLISM IN HIV-1 LIPOATROPHY$376,000
R01 · FY2000 · HL
T CELL KINETICS AND SOURCES--EFFECTS OF HIV AND THERAPY$274,911
R01 · FY2000 · AI
DIRECTLY MEASURED T CELL DYNAMICS IN HIV PATHOGENESIS$265,861
R01 · FY2000 · AI
HEPATIC LIPOGENESIS DURING FRUCTOSE INFUSION$564
M01 · FY2000 · RR
METABOLIC AND KINETIC BASIS OF LDL PATTERNS--EFFECTS OF HIGH CARBOHYDRATE DIET$564
M01 · FY2000 · RR
NUTRITIONAL &GI EFFECTS OF SOLE SOURCE LIQUID FORMULA DIET IN AIDS DIARRHEA$564
M01 · FY2000 · RR
DIRECTLY MEASURED T CELL DYNAMICS IN HIV PATHOGENESIS$564
M01 · FY2000 · RR
ENERGY BALANCE AND METABOLISM IN NONINSULIN DEPENDENT DIABETES MELLITUS$564
M01 · FY2000 · RR
PINITOL--EFFECTS UPON INSULIN SENSITIVITY AND HEPATIC METABOLISM$564
M01 · FY2000 · RR
METABOLIC PATHWAYS, MONOKINES, AND WASTING IN HIV INFECTION$564
M01 · FY2000 · RR
EFFICACY OF ORAL SUPPLEMENTS IN DIARRHEA AND WEIGHT LOSS$564
M01 · FY2000 · RR
METFORMIN AND METABOLISM/BODY COMPOSITION IN HIV/AIDS$0
M01 · FY2000 · RR
EFFICACY OF ORAL SUPPLEMENTS IN DIARRHEA AND WEIGHT LOSS$0
M01 · FY2000 · RR
METABOLIC PATHWAYS, MONOKINES, AND WASTING IN HIV INFECTION$0
M01 · FY2000 · RR
PI AND METABOLISM/BODY COMPOSITION IN HIV - CONTROLS$0
M01 · FY2000 · RR
PI AND METABOLISM/BODY COMPOSITION IN HIV - CONTROLS$0
M01 · FY2000 · RR
PI AND METABOLISM/BODY COMPOSITION IN HIV - CONTROLS$0
M01 · FY2000 · RR
METFORMIN AND METABOLISM/BODY COMPOSITION IN HIV/AIDS$0
M01 · FY2000 · RR
EFFICACY OF ORAL SUPPLEMENTS IN DIARRHEA AND WEIGHT LOSS$0
M01 · FY2000 · RR
METFORMIN AND METABOLISM/BODY COMPOSITION IN HIV/AIDS$0
M01 · FY2000 · RR
SOURCES OF VLDL-TRIGLYCERIDE IN NIDDM$0
M01 · FY2000 · RR
SOURCES OF VLDL-TRIGLYCERIDE IN NIDDM$0
M01 · FY2000 · RR
SOURCES OF VLDL-TRIGLYCERIDE IN NIDDM$0
M01 · FY2000 · RR
DIRECTLY MEASURED T CELL DYNAMICS IN HIV PATHOGENESIS$0
M01 · FY2000 · RR
DIRECTLY MEASURED T CELL DYNAMICS IN HIV PATHOGENESIS$0
M01 · FY2000 · RR
METABOLIC PATHWAYS, MONOKINES, AND WASTING IN HIV INFECTION$0
M01 · FY2000 · RR
HEPATIC LIPOGENESIS DURING FRUCTOSE INFUSION$0
M01 · FY2000 · RR
HEPATIC LIPOGENESIS DURING FRUCTOSE INFUSION$0
M01 · FY2000 · RR